SynAct Pharma AB (OSTO:SYNACT) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:SYNACT SynAct Pharma AB OSTO:SYNACT
30 GF Score
Price kr17.96
! 1 Warning Sign
View Full Analysis

What is SynAct Pharma AB Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


SynAct Pharma AB  (OSTO:SYNACT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


SynAct Pharma AB Cyclically Adjusted PB Ratio Related Terms


SynAct Pharma AB Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for SynAct Pharma AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SynAct Pharma AB Cyclically Adjusted PB Ratio Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 9.42

SynAct Pharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 9.42 6.65 7.64

OSTO:SYNACT vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, SynAct Pharma AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SynAct Pharma AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where SynAct Pharma AB's Cyclically Adjusted PB Ratio falls into.


OSTO:SYNACT
30GF Score
SynAct Pharma AB OSTO:SYNACT
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynAct Pharma AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

SynAct Pharma AB's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, SynAct Pharma AB's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.066/134.6100*134.6100
=3.066

Current CPI (Jun. 2026) = 134.6100.

SynAct Pharma AB Quarterly Data

Book Value per Share CPI Adj_Book
201609 2.554 101.138 3.399
201612 1.958 102.022 2.583
201703 1.779 102.022 2.347
201706 1.485 102.752 1.945
201709 1.334 103.279 1.739
201712 0.922 103.793 1.196
201803 0.733 103.962 0.949
201806 1.468 104.875 1.884
201809 1.048 105.679 1.335
201812 0.649 105.912 0.825
201903 0.404 105.886 0.514
201906 -0.039 106.742 -0.049
201909 -0.242 107.214 -0.304
201912 0.717 107.766 0.896
202003 0.363 106.563 0.459
202006 0.093 107.498 0.116
202009 0.945 107.635 1.182
202012 0.641 108.296 0.797
202103 2.985 108.360 3.708
202106 2.485 108.928 3.071
202109 1.791 110.338 2.185
202112 0.792 112.486 0.948
202203 0.029 114.825 0.034
202206 3.586 118.384 4.078
202209 2.797 122.296 3.079
202212 4.229 126.365 4.505
202303 8.370 127.042 8.869
202306 7.521 129.407 7.823
202309 6.537 130.224 6.757
202312 4.908 131.912 5.008
202403 4.243 132.205 4.320
202406 4.487 132.716 4.551
202409 4.059 132.304 4.130
202412 4.180 132.987 4.231
202503 3.696 132.825 3.746
202506 3.938 133.699 3.965
202509 3.653 133.480 3.684
202512 3.193 133.380 3.222
202603 3.460 133.550 3.487
202606 3.066 134.610 3.066

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


SynAct Pharma AB Business Description

Other Exchanges 8F8:Germany
Address Scheelevagen 2, Lund, SWE, 223 63
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
30GF Score

Get the complete analysis for OSTO:SYNACT

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr17.96
Price